News

ModifyHealth Announces Strategic, Series B Investment from Middleland Capital’s VTC Ventures to Support Increased Demand for its Food-as-Medicine Solutions

ModifyHealth™, an innovative food-as-medicine platform and provider of medically tailored meals, welcomes VTC Ventures as a strategic addition to its Series B investment led by RC Capital and Nashville Capital Network. The funding will support ModifyHealth’s continued growth of its category-leading food-as-medicine solutions and further expansion of its nationwide operations to deliver meaningful patient outcomes.

Middleland Capital is a member of the investment syndicate that recently launched the Food, Nutrition and Health Investor Coalition (FNHIC), which will drive $2.5 billion in private investment over the next three years to improve hunger and health outcomes through food. The coalition plans to highlight and financially support the incredible amount of emerging technological innovation underway that leverages the power of affordable and nutritious food to remediate hunger and improve human health.

Working directly with patients and partnering with payors, employers, and healthcare systems, ModifyHealth’s turnkey FIT™ (Foundation, Immersion, Transition) program decreases cost and improves outcomes for chronic conditions like type 2 diabetes, hypertension, kidney disease, obesity, and irritable bowel syndrome, where dietary management is a recommended treatment.

“Evidence supports what all of us intuitively know – healthy diets and lifestyles are central to preventing, managing, and, in many cases, reversing chronic conditions,” says ModifyHealth Founder & CEO G.B. Pratt. “For many with chronic conditions, the ‘want to’ for a healthier lifestyle exists. It’s the ‘how to’ that remains a challenge. Our program is designed to make the ‘how to’ simple, achievable, and sustainable. We’re excited to partner with VTC Ventures and look forward to impacting lives together.”

“Partnering with high-growth, high-impact companies that deliver enduring value to the healthcare industry and, ultimately, better health outcomes for patients are central to our values,” said James Ramey, JD, Managing Director at VTC Ventures. “ModifyHealth’s team has delivered rapid growth nationally, and we look forward to supporting the company’s mission with this investment.” As part of the VTC Ventures investment, Carilion Clinic – a non-profit healthcare system serving one million people in Virginia’s Blue Ridge and Southwest Virginia – will explore using the ModifyHealth platform in patient care. “The VTC Ventures investment aligns with Carilion’s commitment to including lifestyle medicine as a foundation of healthy outcomes,” said Michael Jeremiah, MD, FAAFP, Chair of Family & Community Medicine and Senior Medical Director of Population Health at Carilion. “Our clinical team is excited about the potential of this platform to support our patients and value-based care initiatives in the communities we serve.”

Recent News

01/20/2026

Vibrent Health Joins a Landmark BARDA-Funded Large-Scale Hybrid/Remote Decentralized Clinical Research Study

Vibrent Health, a leading software-as-a-service (SaaS) data company in the field of precision medicine research, is collaborating with Fred Hutch Cancer Center (Fred Hutch) under a $17 million contract awarded through the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV) Consortium. This collaboration drives critical research on correlates of protection (CoPs),

01/18/2026

Gerry Brunk Joins Focused Ultrasound Foundation’s Council

The Foundation is pleased to welcome Gerry Brunk to its Council, a committed group of goodwill ambassadors who partner with the Board of Directors and staff to offer guidance, raise funds, and generate awareness for focused ultrasound technology. Mr. Brunk co-founded Lumira Ventures, a North American healthcare venture capital firm, and serves as managing director in the firm’s Boston office. He has led investments in

01/14/2026

Phlow and Enveda Partner to Advance AI-Driven Chemistry to Accelerate Domestic Pharmaceutical Development and Transform Drug Substance Manufacturing

Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active Pharmaceutical Ingredient (API) manufacturing process development in collaboration with Enveda, a biotechnology company that learns from life’s chemistry to create better medicines faster. Through a joint pilot program launched last year to rapidly select API